Technical Analysis for REPL - Replimune Group, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 12.24 | -2.08% | -0.26 |
REPL closed up 0.48 percent on Monday, November 11, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | -2.08% | |
NR7 | Range Contraction | -2.08% | |
New 52 Week High | Strength | -2.08% | |
Gapped Up | Strength | -2.08% | |
Upper Bollinger Band Touch | Strength | -2.08% | |
Inside Day | Range Contraction | -1.61% | |
Bearish Engulfing | Bearish | 0.25% | |
Stochastic Sell Signal | Bearish | 0.25% | |
Upper Bollinger Band Walk | Strength | 0.25% | |
Outside Day | Range Expansion | 0.25% |
Alert | Time |
---|---|
Fell Below 10 DMA | about 1 hour ago |
20 DMA Support | about 5 hours ago |
10 DMA Support | about 5 hours ago |
Down 5% | about 5 hours ago |
Down 3% | about 5 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2024
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.97 |
52 Week Low | 4.92 |
Average Volume | 655,914 |
200-Day Moving Average | 8.97 |
50-Day Moving Average | 11.38 |
20-Day Moving Average | 11.89 |
10-Day Moving Average | 12.19 |
Average True Range | 0.63 |
RSI (14) | 59.35 |
ADX | 16.88 |
+DI | 19.42 |
-DI | 14.62 |
Chandelier Exit (Long, 3 ATRs) | 11.08 |
Chandelier Exit (Short, 3 ATRs) | 11.83 |
Upper Bollinger Bands | 12.85 |
Lower Bollinger Band | 10.93 |
Percent B (%b) | 0.82 |
BandWidth | 16.08 |
MACD Line | 0.31 |
MACD Signal Line | 0.28 |
MACD Histogram | 0.0318 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.28 | ||||
Resistance 3 (R3) | 13.35 | 13.16 | 13.15 | ||
Resistance 2 (R2) | 13.16 | 12.96 | 13.13 | 13.11 | |
Resistance 1 (R1) | 12.83 | 12.84 | 12.74 | 12.76 | 13.06 |
Pivot Point | 12.64 | 12.64 | 12.59 | 12.61 | 12.64 |
Support 1 (S1) | 12.31 | 12.44 | 12.22 | 12.24 | 11.94 |
Support 2 (S2) | 12.12 | 12.32 | 12.09 | 11.89 | |
Support 3 (S3) | 11.79 | 12.12 | 11.85 | ||
Support 4 (S4) | 11.72 |